Takeda, Denali drop Alzheimer's asset after phase 1 peak reveals 'narrow therapeutic window'

Takeda and Denali Therapeutics have made the joint decision to end work on their Alzheimer’s disease therapy after a glimpse at early phase 1 data suggested they couldn't pursue the highest dose tested.